Intracellular Delivery III

Market Entry Barriers of Nanomedicines

Nonfiction, Science & Nature, Technology, Nanotechnology, Health & Well Being, Medical
Cover of the book Intracellular Delivery III by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319435251
Publisher: Springer International Publishing Publication: October 31, 2016
Imprint: Springer Language: English
Author:
ISBN: 9783319435251
Publisher: Springer International Publishing
Publication: October 31, 2016
Imprint: Springer
Language: English

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. 

The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. 

Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile. 

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. 

The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. 

Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile. 

More books from Springer International Publishing

Cover of the book Alice Munro by
Cover of the book Deindustrialization and Reindustrialization in Romania by
Cover of the book Illdisciplined Gender by
Cover of the book Mathematics of Program Construction by
Cover of the book Pathological Elements in Analog Circuit Design by
Cover of the book Advances in Artificial Intelligence by
Cover of the book Contemporary Masculinities by
Cover of the book Applied Reconfigurable Computing by
Cover of the book Community-Based Forest Management (CBFM) in Bangladesh by
Cover of the book Conscious Business in Germany by
Cover of the book Composting for Sustainable Agriculture by
Cover of the book Solution Business by
Cover of the book Evolutionary Thinking in Medicine by
Cover of the book Structure-preserving Integrators in Nonlinear Structural Dynamics and Flexible Multibody Dynamics by
Cover of the book Deep Learning and Data Labeling for Medical Applications by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy